Cord Blood News Volume 8.15 | Apr 21 2016

Cryopreservation Has No Effect on Function of Natural Killer Cells Differentiated In Vitro from Umbilical Cord Blood CD34⁺ Cells
Researchers generated large numbers of functional natural killer (NK) cells from cord blood CD34⁺ cells that maintain the same phenotype and function post-cryopreservation, which will allow for multiple infusions of a highly cytotoxic NK cell product. [Cytotherapy] Abstract

Preconditioning in Lowered Oxygen Enhances the Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells in a Rat Model of Spinal Cord Injury
Investigators hypothesized that preconditioning of umbilical cord mesenchymal stem cells in physioxic environment would enhance the regenerative properties of these cells in the treatment of rat spinal cord injury. [Brain Res] Abstract

Conditioned Medium of H9c2 Triggers VEGF Dependent Angiogenesis by Activation of p38/pSTAT3 Pathways in Placenta Derived Stem Cells for Cardiac Repair
Scientists examined the in vitro and in vivo cardiac differentiation potential of human placenta derived stem cells; a unique, abundant, and non-immunogenic cell source. [Life Sci] Abstract

Early Production of Human Neutrophils and Platelets Post-Transplant Is Severely Compromised by Growth Factor Exposure
Investigators showed that exposure of CD34⁺ cord blood cells ex vivo to growth factors that markedly expand their numbers and colony-forming cell content, also rapidly produced a significant and sustained net loss of their original short-term repopulating activity. [Exp Hematol] Abstract

Mesenchymal Stem Cells Differentiated into Chondrocyte-Like Cells
Investigators characterized the ‘stem-ness’ properties of human amniotic fluid derived-mesenchymal stem cells and their potency with regard to the chondrogenic differentiations using the scaffold cultivation method. [Acta Histochem] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

FDA Grants Orphan Drug Exclusivity to EVOMELA™ (Melphalan) for Injection, Indicated for Multiple Myeloma
Spectrum Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted seven years of orphan drug exclusivity for EVOMELA for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. [Spectrum Pharmaceuticals] Press Release

AbbVie, University of Chicago Collaborate to Advance Cancer Research
The University of Chicago and AbbVie have entered into a five-year collaboration agreement designed to improve the pace of discovery and advance medical research in oncology at both organizations. [The University of Chicago] Press Release

From our sponsor: Learn about air-liquid interface culture for respiratory research. Watch the video.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

Postdoctoral Fellow – Hematopoietic Stem Cells (University of Pennsylvania)

Principal Investigator – Stem Cell Biology and Regeneration Medicine (Guangzhou Women and Children’s Medical Center)

Engineering Project Lead (Cytonome)

Postdoctoral Scientist – Hematological Malignancies (Max Delbruck Center for Molecular Medicine in the Helmholtz Association)

Postdoctoral Research Associate – Pediatric Acute Lymphoblastic Leukemia (University of Pittsburgh)

Postdoctoral Research Associate – Blood Stem cell Microenvironment (University of Illinois)

Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine)

Research Associate – Hematopoietic Stem Cell Biology (Editas Medicine)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Research Fellow – Erythropoiesis (New York Blood Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.